Chase is an early stage drug development company, based in Washington, DC. Its mission is to improve the quality of life for those suffering from disorders of brain function, especially cognitive dysfunction of the Alzheimer's type. In the service of this goal, Chase Pharmaceuticals seeks to advance the development of its own intellectual property towards commercial products that satisfy crucial unmet medical needs. Current efforts, focused on pharmaceuticals for Alzheimer type dementia, include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The privately held company received Series A funding in 2010 and 2011 from Brain Trust Accelerator Fund in support of its program of Phase I clinical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/12/14 | $21,000,000 | Series B |
Brain Trust Accelerator Fund Cipla Ventures Edmond de Rothschild Investment Partners New Rhein Healthcare Investors | undisclosed |
